Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll SERMs: meeting the promise of multifunctional medicines Jordan VCJ Natl Cancer Inst 2007[Mar]; 99 (5): 350-6The successful development and clinical evaluation of the selective estrogen receptor modulators in the Study of Tamoxifen and Raloxifene trial provides an occasion to reflect on the milestone that has been achieved and the potential for further progress in the chemoprevention of breast cancer. The evolution of tamoxifen from a successful treatment for breast cancer to the first chemopreventive for any cancer took two decades. Clinicians gained an enormous amount of experience with the use of tamoxifen as a treatment, and, as a result, there were few surprises in terms of efficacy or the side effect profile when the medicine was used to prevent breast cancer in high-risk women. In contrast, raloxifene emerged via the novel path of the evidence-based hypothesis that a drug targeted at one disease, osteoporosis, could also prevent breast cancer. Changes in health care strategies to implement chemoprevention take time, but the evidence now suggests that chemoprevention has become a reality in clinical practice.|Animals[MESH]|Antineoplastic Agents, Hormonal/economics/*pharmacology/*therapeutic use[MESH]|Aromatase Inhibitors/adverse effects[MESH]|Breast Neoplasms/drug therapy/*prevention & control[MESH]|Canada[MESH]|Evidence-Based Medicine[MESH]|Female[MESH]|Humans[MESH]|Neoplasms, Hormone-Dependent/drug therapy/*prevention & control[MESH]|Osteoporosis, Postmenopausal/chemically induced/*prevention & control[MESH]|Raloxifene Hydrochloride/pharmacology/therapeutic use[MESH]|Risk Reduction Behavior[MESH]|Selective Estrogen Receptor Modulators/economics/*pharmacology/*therapeutic use[MESH]|Tamoxifen/pharmacology/therapeutic use[MESH]|United States[MESH] |